{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreih6j5jkjskydgsi27iviiiltnsfvxgb7t5rfxs2yqep5kacik6eq4",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3ml5q3beloc32"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihzr4hqyitlte6wr45fyhc6ljxyhe433ljvg2v5xf4fzuqkinhoei"
    },
    "mimeType": "image/jpeg",
    "size": 114332
  },
  "path": "/news/2026-05-fda-dupixent-chronic-spontaneous-urticaria.html",
  "publishedAt": "2026-05-05T22:40:01.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "The U.S. Food and Drug Administration has approved Sanofi and Regeneron's Dupixent (dupilumab) for the treatment of children (aged 2 to 11 years) with chronic spontaneous urticaria (CSU).",
  "title": "FDA approves Dupixent for chronic spontaneous urticaria in young children"
}